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Background: Millions of patients suffer from medically refractory and disabling 
primary headache disorders. This problem has led to a search for new and innovative 
treatment modalities, including neuromodulation of the occipital nerves. 
Objectives: The primary aim of this study is to describe an implantation technique 
for the Bion® microstimulator and document stimulation parameters and stimulation 
maps after Bion placement adjacent to the greater occipital nerve. The secondary aim 
is to document outcome measures one year post-implant. 
Design: Prospective, observational feasibility study. 
Methods: Nine patients with medically refractory primary headache disorders 
participated in this study. Approximately 6 months after Bion insertion, stimulation 
parameters and maps were documented for all patients. At one year, outcome 
measures were collected including the Migraine Disability Assessment Score. 
Results: At 6 months, the mean perception threshold was 0.47 mA, while the 
mean discomfort threshold was 6.8 mA (stimulation range 0.47 – 6.8 mA). The mean 
paresthesia threshold was 1.64 mA and the mean usage range was 16.0. There were 
no major complications reported such as device migration, infection, or erosion. One 
patient stopped using her Bion before the 12-month follow-up visit. At one year, 7 
of the 8 patients were judged as having obtained fair or better results in terms of 
reduction of disability; 5 patients had greater than a 90% reduction in disability. 
Limitations: Small, heterogeneous patient population without control group. Not 
blinded or randomized.
Conclusion: The Bion can be successfully inserted adjacent to the greater occipital 
nerve in an effort to treat refractory primary headache disorders. This microstimulator 
may provide effective occipital stimulation and headache control while minimizing the 
risks associated with percutaneous or paddle leads implanted subcutaneously in the 
occipital region.
Key words: Chronic headache, migraine, cluster headache, peripheral nerve 
stimulation
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Fig. 1. The Bion microstimulator.
Pain Physician: May/June 2009: 12:621-628
622  www.painphysicianjournal.com
The Bion microstimulator’s small size (27.5 mm x 3.2 
mm) allows implantation adjacent to nerves via a less 
invasive technique than utilizing spinal cord stimula-
tion technology. Previous studies have evaluated Bion 
implantation for pudendal nerve neuromodulation in 
the setting of refractory detrusor overactivity inconti-
nence (14,15). At our institution, we have implanted 9 
Bion microstimulators adjacent to the greater occipital 
nerve (GON) in an effort to treat refractory headache 
disorders. 
The primary aim of this feasibility study is to de-
scribe an implantation technique for the Bion micro-
stimulator and document stimulation parameters and 
stimulation maps after Bion placement adjacent to 
the GON. The secondary aim is to document outcome 
measures one year post-implant.
Methods
After the United States Food and Drug Adminis-
tration (IDE G030225) and Institutional Review Board 
approval of this feasibility study, 9 patients diagnosed 
with chronic migraine or chronic cluster headache 
presenting to our clinic were screened for inclusion 
and exclusion. All 9 patients met the inclusion and ex-
clusion criteria and all agreed to participate. Written 
informed consent was obtained from each. Inclusion 
criteria included 18 years of age or older, 12 or more 
months of chronic migraine or chronic cluster head-
ache, refractory to at least 4 preventative medications 
used at adequate dosage for adequate duration of 
time, willingness to maintain current pain medica-
tion regimen during the study, and willingness and 
ability to maintain a headache diary for the duration 
of the study. Exclusion criteria included pregnancy or 
planned pregnancy, previous surgery in the occipital 
region, and participation in a device or drug trial with-
in the previous 30 days. 
All patients underwent a detailed neurologic 
exam and were assigned a diagnosis based on the In-
ternational Classification of Headache Disorders – II 
(16). Six patients had chronic cluster headache includ-
ing one with migraines and one with hemicrainia con-
tinua, and 3 patients had chronic migraine only (Table 
1). Each patient underwent a psychiatric evaluation 
to determine their psychological stability to undergo 
the procedure. The patients did not undergo a trial of 
stimulation or occipital nerve block before implanta-
tion of the Bion. 
For the purposes of this study, and consistent with 
our previous study on occipital stimulation mapping 
M igraine is the most common form of disabling primary headache, affecting 12% of Caucasian populations (1). Cluster 
headache and hemicrania continua, although much 
less common, also have a significant negative impact 
on quality of life (2,3). Subcutaneous occipital nerve 
stimulation (ONS) has been reported to effectively 
treat medically refractory primary headache disorders. 
A number of recent studies have documented efficacy 
outcomes and stimulation parameters associated with 
ONS (4-10). These studies document off-label use of 
spinal cord stimulation technology to stimulate the 
distal branches of the C1-3 nerve roots. Prospective, 
multicenter studies are underway to determine the 
safety and efficacy of this modality (11).
The implantable Bion microstimulator was ini-
tially developed as a radiofrequency (RF) powered 
functional electrical stimulator (12). However, the 
Bion microstimulator (from Boston Scientific Neuro-
modulation Corporation, Valencia, CA) (Fig. 1) used in 
this study is the only battery powered microstimulator 
of its type and as such does not require an external 
RF power source. It includes a single cathode on one 
end and a single anode on the other. Currently an 
investigational device, the Bion contains a program-
mable microchip, stimulating electrodes, telemetry 
capability, and a transcutaneously rechargeable (3 
milliamp hours) lithium ion battery (13). It is expected 
that the battery will lose no more than 30% of its ca-
pacity after 500 cycles of full charge and discharge. 
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(9), the following definitions were used: perception 
threshold is the lowest current amplitude that elicits 
sensation. Perception threshold is assumed to repre-
sent local tissue stimulation, while the upper end of 
the stimulation range (discomfort threshold) is de-
fined as the current amplitude where patients feel 
stimulation strongly and do not wish the stimulation 
to be increased any further. The stimulation range 
(perception through discomfort threshold) represents 
the useful amplitudes for any given electrode combi-
nation while the usage range (discomfort threshold 
divided by perception threshold) “represents the rela-
tive size of the therapeutic stimulating window” (17). 
Paresthesia threshold is the current amplitude where 
the patient first noted stimulation traveling toward 
the vertex of his head, suggesting direct GON stimu-
lation. The maximum stimulation tested during the 
study was 10 milliamps (mA). 
The Bion implantation procedure was carried out 
under monitored anesthesia care in the prone position. 
Antibiotic prophylaxis was given to each patient before 
incision. The goal of each implant was to position the 
Bion microstimulator subcutaneously in the occipital 
region at a right angle to the GON, with the cathode 
immediately adjacent to the nerve. The anatomy of this 
region has recently been reviewed (8,18), and a cadaver 
study noted that in 10 specimens (20 nerves), the GON 
ascended between 5 and 28 mm from the midline at 
the level of the intermastoid line (19). 
First, using fluoroscopic guidance, a line was 
drawn between the tips of the mastoid processes (in-
termastoid line) and in the midline. After sterile prep 
and injection of local anesthetic for skin wheal, a small 
(< 1 cm) incision was made 3 cm contralateral to the 
side of intended GON stimulation. Next, a 20-gauge, 15 
cm insulated stimulating needle was inserted through 
the incision and across the midline toward the side to 
be stimulated. The ideal depth was estimated to be 
below the dermis but superficial to the fascia, in the 
subcutaneous fat layer. The location of the GON was 
marked as the point where the patient experienced 
maximal stimulation induced paresthesia towards the 
vertex of their head, at least to the level of the top of 
the ear. 
Table 1. Patient demographics, 6-month Bion microstimulator usage and Migraine Disability Assessment Scores (MIDAS).










1 – 72f† Migraine 0.5-1.5 hrs/day 250 60 130-85-4 Did not complete study
2 – 39f Migraine 0.5 hrs,2-3 days/wk 300 55 235-80-4 5-5-5 Excellent
3 – 44f Cluster 0.5-0.75 hrs/2 wks 350 60 270-90-6 260-87-6 Poor
4 – 66f Cluster 5-6 hrs/day 200 45 147-82-7 8-40-7 Excellent
5 – 46m Cluster 22 hrs/day 250 55 225-90-7 130-80-5 Fair
6 – 44f Cluster / hemicrania continua 16 hrs/day 350 45 87-90-5 8-25-4 Excellent
7 – 60m Migraine 18 hrs/day 250 45 108-90-6 6-90-4 Excellent
8 – 44m Cluster 24 hrs/day 300 60 120-88-6 10-85-3 Excellent
9 – 35m Cluster/Migraine 20 hrs/day 200 45 110-90-7 70-60-7 Fair
*Response key:    PPS = pulse per second
> 90% reduction in disability = excellent  †4 month visit
70–90% reduction in disability = very good
50–69% reduction in disability = good
25–49% reduction in disability = fair
< 25% reduction in disability = poor
** The first number of each 3 digit series is the Migraine Disability Assessment Score, the second number is the number of headache days 
over a 3-month period, and the third number is the average severity of each headache. 
Fig. 2. The Bion placement tools and holder. Fig. 3. AP skull film showing Bion after insertion. The 
device is subcutaneous in the occipital region.
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Next, the stimulating needle was removed and 
the Bion introducer with the dissector/stimulator was 
inserted through the incision. The Bion dissector/stim-
ulator was used to confirm the location of the GON, 
after which the Bion was deployed adjacent to the 
GON using the Bion placement tool and holder (Figs. 
2,3). 
Post implantation management included device 
activation 7–10 days postoperatively in 7 of the pa-
tients and activation on the day of implant in 2 pa-
tients. The timing of device activation was based on 
patient preference and travel considerations. The pa-
tients were initially given a radiofrequency “pillow” 
charger; a smaller “butterfly” charger subsequently 
became available that could be attached to a hat, 
allowing the patient to recharge while upright. The 
patients were instructed to initially use the Bion con-
stantly at low amperage and then to increase the am-
perage as needed to treat intermittent headache exac-
erbations. However, they were given the prerogative 
to adjust use to comfort and effect. Patients turned 
stimulation on or off, and adjusted the amplitude of 
stimulation, via a wireless remote control.
Approximately 6 months after implantation, the 
following data were gathered in addition to the data 
collected as part of the sponsored study: headache lo-
cation, average number of hours of Bion use per day, 
frequency of recharging, pulse width and rate, per-
ception threshold with associated paresthesia map, 
discomfort threshold with associated paresthesia map, 
and paresthesia threshold. The patients were given a 
map of the head (Fig. 4) to allow them to identify the 
location of their baseline headaches and areas where 
they perceived stimulation. Mean values with standard 
deviation (SD) were used to summarize the data. 
Migraine Disability Assessment Scores (MIDAS) 
were obtained prior to and at 12 months after implan-
tation of the stimulator. The MIDAS questionnaire is a 
validated headache-related disability instrument that 
is increasingly used as a surrogate measure of outcome 
in episodic and chronic migraine trials (20). The 5-ques-
tion instrument quantifies time lost due to headache 
from work, school, household work, and social/family 
or leisure activities over the preceding 3 months. The 
score is typically reported in a 3-digit format (e.g. 106-
75-7): The first number is the MIDAS (greater than 20 
is considered severe), the second number is the num-
ber of days in the past 3 months that the patient had a 
headache (max 90), and the third number is the aver-
age severity of each headache (0–10 scale). 
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Results
All 9 patients invited to participate signed in-
formed consent. One patient completed the head-
ache maps approximately 4 months after implant. She 
subsequently did not appear for her 6-month follow-
up and stopped using the Bion before study comple-
tion at 12 months. She stated the battery recharging 
schedule was too demanding, specifically that she was 
spending 1.5 hours recharging her Bion for every 1.5 
hours of use. Patient demographics, baseline usage 
data, and MIDAS are summarized in Table 1. The mean 
decrease in number of days with headache for the 8 
patients who completed the study was 28.5 (SD 29.6), 
while the average headache severity score decreased 
by 0.88 (SD 1.36). More detailed outcome data contin-
ues to be analyzed and will be presented separately.
Self-reported stimulator usage ranged from 30 
minutes every 2 weeks to 24 hours/day (mean 12.2 
hours/day, median 16 hours/day), and recharging fre-
quency ranged from 35 minutes per week to 4 hours 
per day (mean 1.67 hours/day, median 1.5 hours/day). 
Distribution of baseline headache and stimulation 
thresholds (perception and discomfort) are shown in 
Table 2 (see Fig. 4 for maps). The zones of stimula-
tion as noted in Table 2 are not meant to imply that 
the patients felt paresthesia throughout the entire 
zone; rather, they recorded stimulation in some part 
of each area noted. Table 3 summarizes stimulation 
parameters, including a mean perception threshold of 
0.47 mA and a mean discomfort threshold of 6.8 mA 
(stimulation range 0.47 – 6.8 mA). The mean pares-
thesia threshold was 1.64 mA, and the mean usage 
range was 16.0. The average tissue impedance was 
1.34 kilo-ohms.
No patients reported major device-related com-
plications during the 12-month duration of the study 
Fig. 4. Head maps used to identify areas of  baseline headache, perception threshold, and discomfort threshold. Used with per-
mission. Trentman et al (9) and the International Neuromodulation Society.
Table 2. Headache and Stimulation Distribution (See Fig. 4). 
This data was obtained at the 6-month follow-up visit (except 




of  Baseline 
Headache
Location of  
Perception 
Threshold
Location of  
Discomfort 
Threshold
1† 1,2,10,11 7,9,18 7
2 5 – 7,9 9 5,7,9
3 10 – 12,14 – 16 16,18 16,18
4 2 – 7, 9,18 7,9 5 – 7,9
5 10,16 16 14 – 16
6 10 – 12,14,16 16 7,14,16
7 10,12,15 18 14,16,18
8 10 – 12 18 7,9,16 – 18
9 1,5,6 1,5 – 7, 9 1,5 – 7,9
†Four month visit.
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such as infection, migration, or erosion. Adverse events 
reported after the study was complete at 12 months 
included loss of stimulation (N = 1). The patient’s Bion 
had malfunctioned and was unrechargeable, requiring 
replacement. This patient subsequently experienced 
an infection necessitating explant and reimplant of a 
third Bion. Minor adverse events included 2 patients 
who complained of muscle stimulation at high ampli-
tudes, and one patient who complained of pain near 
the implant site. 
discusson
Millions of patients suffer from primary headache 
disorders; a portion of them, like the patients in this 
study, endure severe, medically refractory pain. This 
problem has led to a search for new and innovative 
treatment modalities, including neuromodulation of 
the occipital nerves.
A number of recent studies have suggested that 
stimulation of the distal branches of the C1-2-3 nerve 
roots can produce pain relief in patients with otherwise 
refractory headache disorders (21-24). The mechanism 
of analgesia may be due to inhibition of nociceptive 
specific neurons in the trigeminal-cervical complex. 
Electrical stimulation of the GON may also result in mo-
bilization of central pain modulatory centers (25,26). 
Of note, we previously reported pain relief despite 
persistent cranial autonomic activity (lacrimation, rhi-
norrhoea, conjunctival injection) in 2 of these patients 
implanted with Bions (27). One patient was diagnosed 
with cluster headache, while the other was diagnosed 
with hemicrania continua. This separation of autonomic 
signs from analgesia suggests that the autonomic fea-
tures and first division pain are dissociated and sepa-
rately controlled from a supranuclear generator. 
While previous occipital stimulation techniques 
have resulted in diffuse distal C1-2-3 stimulation via 
cylindrical (percutaneous) or paddle (surgical) spinal 
cord stimulator (SCS) leads (4-7), the Bion was used 
here to stimulate a limited area and a specific nerve 
(GON). Our approach assumed that GON stimulation 
will have the same central analgesic affect as more 
diffuse C1-2-3 stimulation via percutaneous stimulator 
leads. If this assumption is correct, clinicians may be 
able to achieve the benefits of occipital stimulation 
via a microstimulator while circumventing the techni-
cal problems associated with occipital percutaneous 
leads and remote power sources. 
In terms of stimulation parameters and the Bion, 
all of the patients had a sensory threshold of less than 
one milliamp, suggesting local tissue stimulation, 
while several patients had discomfort thresholds at 
the maximum tested amplitude of 10 mA. The mean 
paresthesia threshold of 1.64 mA suggests that at this 
amperage the GON was being stimulated directly. The 
large usage range (16.0, SD 8.2) indicates wide varia-
tion between these patients in terms of the size of 
their therapeutic stimulating windows. Lengthy daily 
usage time and high rates of stimulation (pulses per 
second) will increase recharging frequency. 
Table 3. Bion Tested Stimulation Parameters. This data was obtained at the 6-month follow-up visit (except where noted) in addi-









1† 0.6 10.0 1.8 16.67
2 0.2 5.4 1.6 27.0
3 0.4 1.6 1.2 4.0
4 0.2 2.2 0.6 11.0
5 0.8 10.0 1.6 12.5
6 0.4 10.0 4.0 25.0
7 0.4 6.2 1.6 15.5
8 0.8 5.8 1.6 7.25
9 0.4 10.0 0.8 25.0
Mean (SD) 0.47 (0.22) 6.8 (3.4) 1.64 (0.97) 16.0(8.2)
Median 0.4 6.2 1.6 15.5
*Usage range = discomfort threshold divided by perception threshold. †Four month visit.
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Our previous study on occipital paresthesia map-
ping in patients with subcutaneously implanted SCS 
leads provides several points for comparison (9). In that 
study, the mean perception threshold was higher (1.07 
V), while the discomfort threshold (3.63 V) was lower 
than the Bion (Table 3). The average tissue impedance 
in this study (1.34 kilo-ohms) is close to 1.0 kilo-ohms, 
allowing us to assume that the mA recorded for the 
Bion are roughly equivalent to the volts recorded in 
our previous study of SCS leads. The Bion’s proximity to 
the GON may explain its lower perception threshold, 
while the reason for the higher discomfort threshold 
for the Bion is more obscure. Diffuse tissue stimulation 
produced by SCS leads may increase the likelihood of 
patient discomfort.
In terms of paresthesia mapping, it is difficult to 
determine if a correlation exists between distribution 
of paresthesia (Table 2 and Fig. 4) and outcome, but 
a pattern did not appear to emerge. Despite the Bi-
on’s small size, we were able to produce paresthesia 
in remote areas of the head, including at least one 
patient who noted trigeminal distribution paresthe-
sia. It is unknown if outcome is improved by covering 
patient’s baseline headache regions with paresthesia, 
analogous to spinal cord stimulation. 
The MIDAS was used as a measure of outcome in 
this study. At one year, 7 of the 8 patients were judged 
as having obtained fair or better results in terms of 
reduction of disability; 5 patients had greater than 
90% reduction in disability. All patients with excellent 
outcomes experienced a > 50% reduction in headache 
days and/or 30–50% reduction in average headache se-
verity, while patients with a fair response experienced 
a reduction in headache days or severity of 25–50%.
The Bion’s small size and low profile may help 
minimize or eliminate device displacement and lead 
breakage problems associated with SCS equipment 
implanted subcutaneously in the occipital region. As 
recently reviewed (10), complications of SCS systems 
implanted in the occipital region can occur frequently 
with lead migration rates as high as 100%. Other re-
ported complications include lead fracture or discon-
nection, infection, erosion, and allergic reaction.
The Bion microstimulator requires no anchoring 
or tunneling of extensions to remote power sources; 
as such, much of the mechanical stress on the occipi-
tal stimulator system is eliminated. However, it is pos-
sible that a foreign body such as the Bion can move 
within tissue planes or become encapsulated, hence 
increasing the energy required to stimulate the oc-
cipital nerve. As a current controlled device, the Bion 
has the (limited) ability to automatically adjust the 
voltage to maintain the current amplitude despite 
encapsulation.
Disadvantages of a microstimulator system include 
the need for frequent recharging and limited choices 
in terms of electrode combinations. Future versions of 
this device may include a larger battery and multiple 
electrodes.
Limitations of this feasibility study include its small 
and heterogeneous patient population without a con-
trol group. It was neither randomized nor blinded. This 
however was a pilot study to ascertain the feasibility 
of the technique and potential for this modality in the 
treatment of refractory primary headache disorders. 
Thus far, there are no randomized controlled studies 
published on the safety or efficacy of any occipital 
nerve stimulation device for the treatment of primary 
headache disorders. The results of this feasibility study 
would support randomized controlled trials with the 
Bion microstimulator in this patient population. Po-
tentially, a blinded study could be carried out wherein 
Bion microstimulators would be inserted in both a 
treatment and a placebo group. The treatment group 
would receive stimulation immediately after implant, 
while the placebo group would not have their Bion 
microstimulators activated for several months. A 
blinded, head to head comparison of the Bion micro-
stimulator to other ONS systems that use spinal cord 
stimulation equipment could be more difficult to carry 
out, as the spinal cord stimulators systems require a 
remote battery implant. In this scenario, it would not 
be possible to “blind” the patient as to which system 
was implanted. 
conclusion
In conclusion, we have documented paresthesia 
maps and stimulation parameters for 9 patients after 
permanent implantation of a Bion microstimulator, 
with one year outcome data. There were no major ad-
verse events during the study period, including device 
migration or infection. One patient did not complete 
the study. Further studies are needed to evaluate the 
safety and efficacy of subcutaneous C1-2-3 stimula-
tion for headache disorders, including the use of mi-
crostimulators to stimulate specific nerves. If this novel 
microstimulator is shown to be effective in random-
ized trials, it may be possible to achieve headache 
control via neurostimulation with a low incidence of 
long-term complications. 
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